<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-archivearticle1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Microb Genom</journal-id>
    <journal-id journal-id-type="iso-abbrev">Microb Genom</journal-id>
    <journal-id journal-id-type="hwp">mgen</journal-id>
    <journal-id journal-id-type="publisher-id">mgen</journal-id>
    <journal-title-group>
      <journal-title>Microbial Genomics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2057-5858</issn>
    <publisher>
      <publisher-name>Microbiology Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10483414</article-id>
    <article-id pub-id-type="pmid">37552534</article-id>
    <article-id pub-id-type="publisher-id">001081</article-id>
    <article-id pub-id-type="doi">10.1099/mgen.0.001081</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Articles</subject>
        <subj-group subj-group-type="heading">
          <subject>Genomic Methodologies</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Drug resistance prediction for <italic toggle="yes">Mycobacterium tuberculosis</italic> with reference graphs</article-title>
      <alt-title alt-title-type="recto-page-foot">
        <ext-link xlink:href="http://mgen.microbiologyresearch.org" ext-link-type="uri">http://mgen.microbiologyresearch.org</ext-link>
      </alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3683-6208</contrib-id>
        <name>
          <surname>Hall</surname>
          <given-names>Michael B.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="cor1" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8976-2762</contrib-id>
        <name>
          <surname>Lima</surname>
          <given-names>Leandro</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4300-455X</contrib-id>
        <name>
          <surname>Coin</surname>
          <given-names>Lachlan J. M.</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8466-7547</contrib-id>
        <name>
          <surname>Iqbal</surname>
          <given-names>Zamin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cor2" ref-type="corresp">*</xref>
      </contrib>
      <aff id="aff1"><label><sup>1</sup>​</label><institution>European Molecular Biology Laboratory, European Bioinformatics Institute</institution>, <addr-line content-type="city">Hinxton</addr-line>, <addr-line content-type="state">Cambridgeshire</addr-line>, <country>UK</country></aff>
      <aff id="aff2"><label><sup>2</sup>​</label><institution content-type="department">Department of Microbiology and Immunology</institution>, <institution>Peter Doherty Institute for Infection and Immunity, The University of Melbourne</institution>, <addr-line content-type="city">Melbourne</addr-line>, <country>Australia</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><bold>*Correspondence:</bold> Michael B. Hall, <email xlink:href="mailto:michael.hall2@unimelb.edu.au">michael.hall2@unimelb.edu.au</email>
</corresp>
      <corresp id="cor2"><bold>*Correspondence:</bold> Zamin Iqbal, <email xlink:href="mailto:zi@ebi.ac.uk">zi@ebi.ac.uk</email>
</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>8</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>8</day>
      <month>8</month>
      <year>2023</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>9</volume>
    <issue>8</issue>
    <elocation-id>mgen001081</elocation-id>
    <history>
      <date date-type="received">
        <day>09</day>
        <month>5</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>7</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="mgen-9-1081.pdf"/>
    <abstract>
      <p>Tuberculosis is a global pandemic disease with a rising burden of antimicrobial resistance. As a result, the World Health Organization (WHO) has a goal of enabling universal access to drug susceptibility testing (DST). Given the slowness of and infrastructure requirements for phenotypic DST, whole-genome sequencing, followed by genotype-based prediction of DST, now provides a route to achieving this. Since a central component of genotypic DST is to detect the presence of any known resistance-causing mutations, a natural approach is to use a reference graph that allows encoding of known variation. We have developed DrPRG (Drug resistance Prediction with Reference Graphs) using the bacterial reference graph method Pandora. First, we outline the construction of a <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">Mycobacterium tuberculosis</ext-link></named-content></italic> drug resistance reference graph. The graph is built from a global dataset of isolates with varying drug susceptibility profiles, thus capturing common and rare resistance- and susceptible-associated haplotypes. We benchmark DrPRG against the existing graph-based tool Mykrobe and the haplotype-based approach of TBProfiler using 44 709 and 138 publicly available Illumina and Nanopore samples with associated phenotypes. We find that DrPRG has significantly improved sensitivity and specificity for some drugs compared to these tools, with no significant decreases. It uses significantly less computational memory than both tools, and provides significantly faster runtimes, except when runtime is compared to Mykrobe with Nanopore data. We discover and discuss novel insights into resistance-conferring variation for <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">M. tuberculosis</ext-link></named-content></italic> – including deletion of genes <italic toggle="yes">katG</italic> and <italic toggle="yes">pncA</italic> – and suggest mutations that may warrant reclassification as associated with resistance.</p>
    </abstract>
    <kwd-group>
      <kwd>genome graphs</kwd>
      <kwd>reference graphs</kwd>
      <kwd>drug resistance prediction</kwd>
      <kwd>
        <italic toggle="yes">Mycobacterium tuberculosis</italic>
      </kwd>
      <kwd>benchmark</kwd>
      <kwd>software</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>Australian Government Medical Research Future Fund</funding-source>
        <award-id>2020/MRF1200856</award-id>
        <principal-award-recipient>MichaelB Hall</principal-award-recipient>
      </award-group>
      <award-group>
        <funding-source>Australian Government Medical Research Future Fund </funding-source>
        <award-id>2020/MRF1200856</award-id>
        <principal-award-recipient>LachlanJ M Coin</principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>OpenAccessEmbargo</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="s2">
    <title>Data Summary</title>
    <p>The authors confirm all supporting data, code and protocols have been provided within the article or through supplementary data files.</p>
    <p>The software method presented in this work, DrPRG, is freely available from GitHub under an MIT licence at <ext-link xlink:href="https://github.com/mbhall88/drprg" ext-link-type="uri">https://github.com/mbhall88/drprg</ext-link>. We used commit <ext-link xlink:href="https://github.com/mbhall88/drprg/tree/9492f256ffb0026fec756125f7b7a61e668dc3d5" ext-link-type="uri">9492</ext-link> f25 for all results via a Singularity [<xref rid="R1" ref-type="bibr">1</xref>] container from the URI docker://quay.io/mbhall88/drprg:9492 f25.</p>
    <p>All code used to generate results for this study is available on GitHub at <ext-link xlink:href="https://github.com/mbhall88/drprg-paper" ext-link-type="uri">https://github.com/mbhall88/drprg-paper</ext-link>. All data used in this work are freely available from the SRA/ENA/DRA and a copy of the datasheet with all associated phenotype information can be downloaded from the archived repository at <ext-link xlink:href="https://doi.org/10.5281/zenodo.7819984" ext-link-type="uri">https://doi.org/10.5281/zenodo.7819984</ext-link> or found in the previously mentioned GitHub repository.</p>
    <p>The <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">Mycobacterium tuberculosis</ext-link></named-content></italic> index used in this work is available to download through DrPRG via the command drprg index --download mtb@20230308 or from GitHub at <ext-link xlink:href="https://github.com/mbhall88/drprg-index" ext-link-type="uri">https://github.com/mbhall88/drprg-index</ext-link>.</p>
    <boxed-text position="float">
      <caption>
        <title>Impact Statement</title>
      </caption>
      <p><italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">Mycobacterium tuberculosis</ext-link></named-content></italic> is the bacterium responsible for tuberculosis (TB). TB is one of the leading causes of death worldwide; before the coronavirus pandemic it was the leading cause of death from a single pathogen. Drug-resistant TB incidence has recently increased, making the detection of resistance even more vital. In this study, we develop a new software tool to predict drug resistance from whole-genome sequence data of the pathogen using new reference graph models to represent a reference genome. We evaluate it on <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">M. tuberculosis</ext-link></named-content></italic> against existing tools for resistance prediction and show improved performance. Using our method, we discover new resistance-associated variations and discuss reclassification of a selection of existing mutations. As such, this work contributes to TB drug resistance diagnostic efforts. In addition, the method could be applied to any bacterial species, so is of interest to anyone working on antimicrobial resistance.</p>
    </boxed-text>
  </sec>
  <sec sec-type="intro" id="s3">
    <title>Introduction</title>
    <p>Human industrialization of antibiotic production and use over the last 100 years has led to a global rise in the prevalence of antibiotic-resistant bacterial strains. The phenomenon was even observed within patients in the first clinical trial of streptomycin as a drug for tuberculosis (TB) in 1948 [<xref rid="R2" ref-type="bibr">2</xref>], and indeed as every new drug class has been introduced, so has resistance followed. Resistance mechanisms are varied, and can be caused by point mutations at key loci (e.g. binding sites of drugs [<xref rid="R3" ref-type="bibr">3, 4</xref>]), frameshifts rendering a gene non-functional [<xref rid="R5" ref-type="bibr">5</xref>], horizontal acquisition of new functionality via a new gene [<xref rid="R6" ref-type="bibr">6</xref>], or upregulation of efflux pumps to reduce the drug concentration within the cell [<xref rid="R7" ref-type="bibr">7</xref>].</p>
    <p>Phenotypic and genotypic methods for detecting reduced susceptibility to drugs play complementary roles in clinical microbiology. Carefully defined phenotypic assays are used to give (semi)quantitative or binary measures of drug susceptibility; these have the benefit of being experimental, quantitative measurements, and can detect resistance caused by hitherto unknown mechanisms. Prediction of drug resistance from genomic data has different advantages. Detection of a single-nucleotide polymorphism (SNP) is arguably more consistent than a phenotypic assay, as it is not affected by whether the resistance it causes is near some threshold defining a resistant/susceptible boundary. Additionally, combining sequence datasets from different laboratories is more reliable than combining different phenotypic datasets, and using sequence data allows one to detect informative genetic changes (e.g. a tandem expansion of a single gene to form an array, thus increasing dosage). More subtly, defining the cut-off to separate resistant from susceptible is only simple when the minimum inhibitory concentration distribution is a simple bimodal distribution; in reality it is sometimes a convolution of multiple distributions caused by different mutations, and genetic data are sometimes needed to deconvolve the data and choose a threshold [<xref rid="R8" ref-type="bibr">8, 9</xref>].</p>
    <p>The key requirement for a genomic predictor is to have an encodable understanding of the genotype-to-phenotype map. Research has focused on clinically important pathogens, primarily <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.3093" ext-link-type="uri">Escherichia coli</ext-link></named-content></italic>, <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10789" ext-link-type="uri">Klebsiella pneumoniae</ext-link></named-content></italic>, <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.11017" ext-link-type="uri">Salmonella enterica</ext-link></named-content></italic>, <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.2553" ext-link-type="uri">Pseudomonas aeruginosa</ext-link></named-content></italic> and <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">Mycobacterium tuberculosis</ext-link></named-content></italic> (MTB). The challenges differ across species; almost all bacterial species are extremely diverse, with non-trivial pan-genomes and considerable horizontal gene transfer causing transmission of resistance genes [<xref rid="R10" ref-type="bibr">10</xref>]. In these cases, species are so diverse that detection of chromosomal SNPs is heavily affected by reference bias [<xref rid="R11" ref-type="bibr">11</xref>]. Furthermore, there is an appreciable proportion of resistance that is not currently explainable through known SNPs or genes [<xref rid="R12" ref-type="bibr">12–14</xref>]. At the other extreme, MTB has almost no accessory genome, and no recombination or plasmids [<xref rid="R15" ref-type="bibr">15</xref>]. Resistance appears to be caused entirely by mutations, insertion/deletions (indels) and rare structural variants, and simple sets of rules (‘if any of these mutations are present, or any of these genes inactivated, the sample is resistant’) work well for most drugs [<xref rid="R16" ref-type="bibr">16</xref>]. MTB has an exceptionally slow growth rate, meaning that culture-based drug susceptibility testing (DST) is slow (2–4 weeks, depending on media), and therefore sequencing is faster [<xref rid="R17" ref-type="bibr">17</xref>]. As part of the end TB strategy, the World Health Organization (WHO) strives towards universal access to DST [<xref rid="R18" ref-type="bibr">18</xref>], defining target product profiles for molecular diagnostics [<xref rid="R19" ref-type="bibr">19, 20</xref>] and publishing a catalogue of high-confidence resistance mutations intended to provide a basis for commercial diagnostics and future research [<xref rid="R16" ref-type="bibr">16</xref>]. There was a strong community-wide desire to integrate this catalogue into software for genotypic resistance prediction, although independent benchmarking confirmed that there was still need for improvement [<xref rid="R12" ref-type="bibr">12</xref>]. Hence, there is a continuing need to improve the understanding of the genetic basis of resistance and integrate it into software for genotypic DST.</p>
    <p>In this paper we develop and evaluate a new software tool for genotypic DST for MTB, built on a generic framework that could be used for any bacteria. Several tools have been developed previously [<xref rid="R21" ref-type="bibr">21–25</xref>]. Of these, only Mykrobe and TBProfiler work on Illumina and Nanopore data, and both have been heavily evaluated previously [<xref rid="R22" ref-type="bibr">22, 23, 26, 27</xref>] – so we benchmark against these. Mykrobe uses de Bruijn graphs to encode known resistance alleles and thereby achieves high accuracy even on indel calls with Nanopore data [<xref rid="R27" ref-type="bibr">27</xref>]. However, it is unable to detect novel alleles in known resistance genes, nor to detect gene truncation or deletion, which would be desirable. TBProfiler is based on mapping and variant calling (by default using Freebayes [<xref rid="R28" ref-type="bibr">28</xref>]) and detects gene deletions using Delly [<xref rid="R29" ref-type="bibr">29</xref>].</p>
    <p>Our new software, called DrPRG (Drug resistance Prediction with Reference Graphs), builds on newer pan-genome technology than Mykrobe [<xref rid="R11" ref-type="bibr">11</xref>] using an independent graph for each gene in the catalogue, which makes it easier to go back and forth between VCF and the graph. To build an index, it takes as input a catalogue of resistant variants (a simple four-column TSV file), a file specifying expert rules (e.g. any missense variant between codons X and Y in gene Z causes resistance to drug W) and a VCF of population variation in the genes of interest. This allows it to easily incorporate the current WHO-endorsed catalogue [<xref rid="R16" ref-type="bibr">16</xref>], which is conservative, and for the user to update the catalogue or rules with minimal effort. Finally, to provide resistance predictions, it takes a prebuilt index (an MTB one is currently provided) and sequencing reads (FASTQ).</p>
    <p>We describe the DrPRG method, and to evaluate it, gather the largest MTB dataset of sequencing data with associated phenotype information and reveal novel insights into resistance-determining mutations for this species.</p>
  </sec>
  <sec sec-type="methods" id="s4">
    <title>Methods</title>
    <p>DrPRG is a command-line software tool implemented in the Rust programming language. There are two main subcommands: <italic toggle="yes">build</italic> for building a reference graph and associated index files, and <italic toggle="yes">predict</italic> for producing genotypic resistance predictions from sequencing reads and an index (from <italic toggle="yes">build</italic>).</p>
    <sec id="s4-1">
      <title>Constructing a resistance-specific reference graph and index</title>
      <p>The <italic toggle="yes">build</italic> subcommand of DrPRG requires a variant call format (VCF) file of variants from which to build a reference graph, a catalogue of mutations that confer resistance or susceptibility for one or more drugs and an annotation (GFF) and FASTA file of the reference genome.</p>
      <p>For this work, we used the reference and annotation for the MTB strain H37Rv (accession NC_000962.3) and the default mutation catalogue from Mykrobe (v0.12.1) [<xref rid="R12" ref-type="bibr">12, 26</xref>].</p>
      <p>To ensure the reference graph is not biased towards a particular lineage or susceptibility profile, we selected samples from a VCF of 15 211 global MTB samples [<xref rid="R30" ref-type="bibr">30</xref>]. We randomly chose 20 samples from each lineage 1 through 4, as well as 20 samples from all other lineages combined. In addition, we included 17 clinical samples representing MTB global diversity (lineages 1–6) [<xref rid="R31" ref-type="bibr">31, 32</xref>] to give a total of 117 samples. In the development phase of DrPRG we also found it necessary to add some common mutations not present in these 117 samples; as such, we added 48 mutations to the global VCF (these mutations were selected as they were the most common minor allele-causing mutations that were not in the reference graph and are listed in the archived repository – see Data Summary). We did not add all catalogue mutations as there is a saturation point for mutation addition to a reference graph, and beyond this point, performance begins to decay (see Sections S1 and S2, available in the online version of this article and [<xref rid="R33" ref-type="bibr">33</xref>]).</p>
      <p>The <italic toggle="yes">build</italic> subcommand turns this VCF into a reference graph by extracting a consensus sequence for each gene and sample. We use just those genes that occur in the mutation catalogue and include 100 bases flanking the gene. A multiple sequence alignment is constructed for each gene from these consensus sequences with MAFFT (v7.505) [<xref rid="R34" ref-type="bibr">34, 35</xref>] and then a reference graph is constructed from these alignments with make_prg (v0.4.0) [<xref rid="R11" ref-type="bibr">11</xref>]. The final reference graph is then indexed with Pandora [<xref rid="R11" ref-type="bibr">11</xref>].</p>
    </sec>
    <sec id="s4-2">
      <title>Genotypic resistance prediction</title>
      <p>Genotypic resistance prediction of a sample is performed by the <italic toggle="yes">predict</italic> subcommand of DrPRG. It takes an index produced by the <italic toggle="yes">build</italic> command (see Constructing a resistance-specific reference graph and index) and sequencing reads – Illumina or Nanopore are accepted. To generate predictions, DrPRG discovers novel variants (Pandora), adds these to the reference graph (make_prg and MAFFT) and then genotypes the sample with respect to this updated graph (Pandora). The genotyped VCF is filtered such that we ignore any variant with fewer than three reads supporting it and require a minimum of 1 % read depth on each strand (Section S2). Next, each variant is compared to the catalogue. If an alternative allele has been called that corresponds with a catalogue variant, resistance (‘R’) is noted for the drug(s) associated with that mutation. If a variant in the VCF matches a catalogue mutation, but the genotype is null (‘.’), we mark that mutation, and its associated drug(s), as failed (‘F’). Where an alternative allele call does not match a mutation in the catalogue, we produce an unknown (‘U’) prediction for the drug(s) that have a known resistance-conferring mutation in the relevant gene.</p>
      <p>DrPRG also has the capacity to detect minor alleles and call minor resistance (‘r’) or minor unknown (‘u’) in such cases. Minor alleles are called when a variant (that has passed the above filtering) is genotyped as being the susceptible (reference) allele, but there is also read depth on the resistant (alternate) allele above a given minor allele frequency parameter (--maf; default is 0.1 for Illumina data). Minor allele calling is turned off by default for Nanopore data, as we found it led to a drastic increase in the number of false-positive calls (this is also the case for Mykrobe and TBProfiler).</p>
      <p>When building the index for DrPRG and making predictions, we also accept a file of ‘expert rules’ for calling variants of a certain class. A rule is associated with a gene, an optional position range, a variant type and the drug(s) that rule confers resistance to. Currently supported variant types are missense, nonsense, frameshift and gene absence.</p>
      <p>The output of running <italic toggle="yes">predict</italic> is a VCF file of all variants in the graph and a JSON file of resistance predictions for each drug in the index, along with the mutation(s) supporting that prediction and a unique identifier to find that variant in the VCF file (see Section S3 for an example). The reference graph gene presence/absence (as determined by Pandora) is also listed in the JSON file.</p>
    </sec>
    <sec id="s4-3">
      <title>Benchmark</title>
      <p>We compare the performance of DrPRG against Mykrobe (v0.12.1) [<xref rid="R26" ref-type="bibr">26</xref>] and TBProfiler (v4.3.0) [<xref rid="R22" ref-type="bibr">22</xref>] for MTB drug resistance prediction. Mykrobe is effectively a predecessor of DrPRG; it uses genome graphs, in the form of de Bruijn graphs, to construct a graph of all mutations in a catalogue and then genotypes the reads against this graph. TBProfiler is a more traditional approach which aligns reads to a single reference genome and calls variants from that via aligned haplotype sequences.</p>
      <p>A key part of such a benchmark is the catalogue of mutations, as this generally accounts for the majority of differences between tools [<xref rid="R26" ref-type="bibr">26</xref>]. As such, we use the same catalogue for all tools to ensure that any differences are method-related and not catalogue disparities. The catalogue we chose is the default one provided in Mykrobe [<xref rid="R12" ref-type="bibr">12</xref>]. It is a combination of the catalogue described in Hunt <italic toggle="yes">et al.</italic> [<xref rid="R26" ref-type="bibr">26</xref>] and the category 1 and 2 mutation and expert rules from the 2021 WHO catalogue [<xref rid="R16" ref-type="bibr">16</xref>]. This catalogue contains mutations for 14 drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, levofloxacin, moxifloxacin, ofloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, linezolid and delamanid.</p>
      <p>We used Mykrobe and TBProfiler with default parameters, except for a parameter in each indicating the sequencing technology of the data as Illumina or Nanopore and the TBProfiler option to not trim data (as we do this in quality control).</p>
      <p>We compare the prediction performance of each program using sensitivity and specificity. To calculate these metrics, we consider a true positive (TP) and true negative (TN) as a case where a program calls resistant and susceptible, respectively, and the phenotype agrees; a false positive (FP) as a resistant call by a program but a susceptible phenotype, with false negatives (FNs) being the inverse of FPs. We only present results for drugs in the catalogue and where at least 10 samples had phenotypic data available.</p>
      <p>To benchmark the runtime and memory usage of each tool, we used the Snakemake benchmark feature within our analysis pipeline [<xref rid="R36" ref-type="bibr">36</xref>].</p>
    </sec>
    <sec id="s4-4">
      <title>Datasets</title>
      <p>We gathered various MTB datasets where whole-genome sequencing data (Nanopore or Illumina) were available from public repositories (ENA/SRA/DRA) and associated phenotypes were accessible for at least one drug present in our catalogue [<xref rid="R16" ref-type="bibr">16, 27, 37–49</xref>].</p>
      <p>All data were downloaded with fastq-dl (v1.1.1; <ext-link xlink:href="https://github.com/rpetit3/fastq-dl" ext-link-type="uri">https://github.com/rpetit3/fastq-dl</ext-link>).</p>
    </sec>
    <sec id="s4-5">
      <title>Quality control</title>
      <p>All downloaded Nanopore fastq files had adapters trimmed with porechop (v0.2.4; <ext-link xlink:href="https://github.com/rrwick/Porechop" ext-link-type="uri">https://github.com/rrwick/Porechop</ext-link>), with the option to discard any reads with an adapter in the middle, and any reads with an average quality score below 7 were removed with nanoq (v0.9.0) [<xref rid="R50" ref-type="bibr">50</xref>]. Illumina reads were preprocessed with fastp (v0.23.2) [<xref rid="R51" ref-type="bibr">51</xref>] to remove adapter sequences, trim low-quality bases from the ends of the reads, and remove duplicate reads and reads shorter than 30 bp.</p>
      <p>Sequencing reads were decontaminated as described by Hall <italic toggle="yes">et al.</italic> [<xref rid="R27" ref-type="bibr">27</xref>] and Walker <italic toggle="yes">et al.</italic> [<xref rid="R16" ref-type="bibr">16</xref>]. Briefly, sequenced reads were mapped to a database of common sputum contaminants and the MTB reference genome (H37Rv; accession NC_000962.3) [<xref rid="R52" ref-type="bibr">52</xref>], only keeping those reads where the best mapping was to H37Rv.</p>
      <p>After quality control, we removed any sample with an average read depth &lt;15, or where more than 5 % of the reads mapped to contaminants.</p>
      <p>Lineage information was extracted from the TBProfiler results (see Benchmark).</p>
    </sec>
    <sec id="s4-6">
      <title>Statistical analysis</title>
      <p>We used a Wilcoxon rank-sum paired data test from the Python library SciPy [<xref rid="R53" ref-type="bibr">53</xref>] to test for significant differences in runtime and memory usage between the three prediction tools.</p>
      <p>The sensitivity and specificity confidence intervals were calculated with a Wilson’s score interval with a coverage probability of 95 %.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s5">
    <title>Results</title>
    <p>To benchmark DrPRG, Mykrobe and TBProfiler, we gathered an Illumina dataset of 45 702 MTB samples with a phenotype for at least 1 drug. After quality control (see Quality control), this number reduced to 44 709. In addition, we gathered 142 Nanopore samples, of which 138 passed quality control. In <xref rid="F1" ref-type="fig">Fig. 1</xref> we show all available drug phenotypes for those interested in the dataset, although our catalogue does not offer predictions for all drugs listed (see Benchmark). Lineage counts for all samples that passed quality control and have a single, major lineage call can be found in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
    <fig position="float" fig-type="figure" id="F1">
      <label>Fig. 1.</label>
      <caption>
        <p>Drug phenotype counts for Illumina (upper) and Nanopore (lower) datasets. Bars are stratified and coloured by whether the phenotype is resistant (R; orange) or susceptible (S; green). Note, the <italic toggle="yes">y</italic>-axis is log-scaled. PAS para-aminosalicylic acid.</p>
      </caption>
      <graphic xlink:href="mgen-9-1081-g001" position="float"/>
    </fig>
    <table-wrap position="float" id="T1">
      <label>Table 1.</label>
      <caption>
        <p>Lineage counts from the Illumina and Nanopore datasets, covering the main lineages 1–9 (L1–L9) and the three livestock-associated lineages (La1–La3), as defined in [<xref rid="R80" ref-type="bibr">80</xref>]</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <p>Lineage</p>
            </th>
            <th align="center" valign="top" rowspan="1" colspan="1">
              <p>Illumina</p>
            </th>
            <th align="center" valign="top" rowspan="1" colspan="1">
              <p>Nanopore</p>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>La1</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>239</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>La2</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>7</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>La3</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>71</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L1</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>3907</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>32</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L2</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>12 870</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>38</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L3</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>5803</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>9</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L4</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>20 731</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>59</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L5</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>63</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L6</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>78</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L7</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>3</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <p>L9</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>1</p>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <p>0</p>
            </td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <sec id="s5-1">
      <title>Sensitivity and specificity performance</title>
      <p>We present the sensitivity and specificity results for Illumina data in <xref rid="F2" ref-type="fig">Fig. 2</xref> and Table S2 and the Nanopore data in <xref rid="F3" ref-type="fig">Fig. 3</xref> and Table S3.</p>
      <fig position="float" fig-type="figure" id="F2">
        <label>Fig. 2.</label>
        <caption>
          <p>Sensitivity (upper panel; <italic toggle="yes">y</italic>-axis) and specificity (lower panel; <italic toggle="yes">y</italic>-axis) of resistance predictions for different drugs (<italic toggle="yes">x</italic>-axis) from Illumina data. Error bars are coloured by prediction tool. The central horizontal line in each error bar is the sensitivity/specificity and the error bars represent the 95 % confidence interval. Note, the sensitivity panel’s <italic toggle="yes">y</italic>-axis is logit-scaled. This scale is similar to a log scale close to zero and to one (100%), and almost linear around 0.5 (50 %). The red dashed line in each panel represents the minimal standard WHO target product profile (TPP; where available) for next-generation drug susceptibility testing for sensitivity and specificity. INH isoniazid; RIF, rifampicin; EMB, ethambutol; PZA, pyrazinamide; LFX, levofloxacin; MFX, moxifloxacin; OFX, ofloxacin; AMK, amikacin; CAP, capreomycin; KAN, kanamycin; STM, streptomycin; ETO, ethionamide; LZD, linezolid; DLM, delamanid.</p>
        </caption>
        <graphic xlink:href="mgen-9-1081-g002" position="float"/>
      </fig>
      <fig position="float" fig-type="figure" id="F3">
        <label>Fig. 3.</label>
        <caption>
          <p>Sensitivity (upper panel; <italic toggle="yes">y</italic>-axis) and specificity (lower panel; <italic toggle="yes">y</italic>-axis) of resistance predictions for different drugs (<italic toggle="yes">x</italic>-axis) from Nanopore data. Error bars are coloured by prediction tool. The central horizontal line in each error bar is the sensitivity/specificity and the error bars represent the 95 % confidence interval. Note, the sensitivity panel’s <italic toggle="yes">y</italic>-axis is logit-scaled. This scale is similar to a log scale close to zero and to one (100%), and almost linear around 0.5 (50 %). The red dashed line in each panel represents the minimal standard WHO target product profile (TPP; where available) for next-generation drug susceptibility testing for sensitivity and specificity. INH isoniazid; RIF, rifampicin; EMB, ethambutol; OFX, ofloxacin; AMK, amikacin; CAP, capreomycin; KAN, kanamycin; STM, streptomycin; ETO, ethionamide.</p>
        </caption>
        <graphic xlink:href="mgen-9-1081-g003" position="float"/>
      </fig>
      <p>When comparing DrPRG’s performance to that of Mykrobe and TBProfiler, we look for instances where the confidence intervals do not overlap, indicating a significant difference. With Illumina data (<xref rid="F2" ref-type="fig">Fig. 2</xref> and Table S), DrPRG achieves significantly greater sensitivity than Mykrobe for rifampicin [96.4 % (96.0–96.7) vs 95.6 % (95.2–95.9)], streptomycin [85.3 % (84.4–86.3) vs 83.1 % (82.1–84.1)], amikacin [85.6 % (83.9–87.1) vs 80.8 % (78.9–82.5)], capreomycin [77.5 % (75.2–79.7) vs 71.8 % (69.3–74.1)], kanamycin [83.7 % (82.1–85.2) vs 79.9 % (78.2–81.5)] and ethionamide [75.2 % (73.7–76.8) vs 71.4 % (69.7–73.0)], with no significant difference for all other drugs. In terms of sensitivity, there was no significant difference between DrPRG and TBProfiler except for ethionamide, where DrPRG was significantly more sensitive [75.2 % (73.7–76.8) vs 71.5 % (69.8–73.1)]. For specificity, there was no significant difference between the tools except that DrPRG and Mykrobe were significantly better than TBProfiler for rifampicin [97.8 % (97.6–98.0) vs 97.2 % (97.0–97.4)]. There was no significant difference in sensitivity or specificity for any drug with Nanopore data.</p>
      <p>In both figures, we show the minimal requirements from the WHO target product profiles for the sensitivity and specificity of genotypic drug susceptibility testing [<xref rid="R19" ref-type="bibr">19</xref>] as red dashed lines. Note, a sensitivity target is not specified by the WHO for ethambutol (EMB), capreomycin (CAP), kanamycin (KAN), streptomycin (STM), or ethionamide (ETO). For Illumina data, all tools’ predictions for rifampicin, isoniazid, levofloxacin, moxifloxacin and amikacin are above the sensitivity minimal requirement target. TBProfiler also exceeds the target for pyrazinamide, which DrPRG misses by 0.2 %. No drug’s sensitivity target was achieved with Nanopore data. For specificity, the tools are all very similar and either exceed or fall below the threshold together (see <xref rid="F2" ref-type="fig">Fig. 2</xref>). The target of &gt;98 % is only met by all tools with Illumina data for ofloxacin, amikacin, linezolid and delamanid. Mykrobe also exceeds the target for capreomycin. As such, amikacin is the only drug where both sensitivity and specificity performance exceed the minimal requirement of the WHO target product profiles. Only capreomycin and kanamycin specificity targets are exceeded (by all tools) with Nanopore data.</p>
      <p>However, for Illumina data, we did find that likely sample swaps or phenotype instability [<xref rid="R54" ref-type="bibr">54</xref>] could lead to some drugs being on the threshold of the WHO target product profiles. If we excluded samples where all three tools make a FP call for the strong isoniazid and rifampicin resistance-conferring mutations <italic toggle="yes">katG</italic> S315T (<italic toggle="yes">n</italic>=152) and <italic toggle="yes">rpoB</italic> S450L (<italic toggle="yes">n</italic>=119) [<xref rid="R16" ref-type="bibr">16</xref>], respectively, all three tools would exceed the isoniazid specificity target of 98 % – thus meeting both sensitivity and specificity targets for isoniazid. In addition, DrPRG and Mykrobe would meet the rifampicin specificity target of 98 % – leading to both targets being met for rifampicin for these two tools. As previously reported [<xref rid="R54" ref-type="bibr">54, 55</xref>], we also found considerable instability in the ethambutol result caused by <italic toggle="yes">embB</italic> mutations M306I (<italic toggle="yes">n</italic>=827) and M306V (<italic toggle="yes">n</italic>=519) being called for phenotypically susceptible samples (FP) by all three tools. Other frequent consensus FP calls included <italic toggle="yes">fabG1</italic> c-15t, which is associated with ethionamide (<italic toggle="yes">n</italic>=441) and isoniazid (<italic toggle="yes">n</italic>=241) resistance, and <italic toggle="yes">rrs</italic> a1401g, which is associated with resistance to capreomycin (<italic toggle="yes">n</italic>=241), amikacin (<italic toggle="yes">n</italic>=70) and kanamycin (<italic toggle="yes">n</italic>=48). In addition, there were common false positives from <italic toggle="yes">gyrA</italic> mutations A90V and D94G, which are associated with resistance to the fluoroquinolones levofloxacin (<italic toggle="yes">n</italic>=108 and <italic toggle="yes">n</italic>=70, respectively), moxifloxacin (<italic toggle="yes">n</italic>=419 and <italic toggle="yes">n</italic>=349) and ofloxacin (<italic toggle="yes">n</italic>=19 and <italic toggle="yes">n</italic>=17), and are known to cause heteroresistance and minimum inhibitory concentrations (MICs) close to the critical concentration threshold [<xref rid="R56" ref-type="bibr">56–58</xref>].</p>
    </sec>
    <sec id="s5-2">
      <title>Evaluation of potential additions to the WHO catalogue</title>
      <p>False negatives are much harder to investigate because it is not known which mutation(s) were missed, as they are presumably not in the catalogue if all tools failed to make a call. However, looking through those FNs where DrPRG makes an ‘unknown’ resistance call, we note some potential mutations that may require reclassification or inclusion in the WHO catalogue. For delamanid FNs, we found five different nonsense mutations in the <italic toggle="yes">ddn</italic> gene in seven samples – W20* (<italic toggle="yes">n</italic>=2), W27* (<italic toggle="yes">n</italic>=1), Q58* (<italic toggle="yes">n</italic>=1), W88* (<italic toggle="yes">n</italic>=2) and W139* (<italic toggle="yes">n</italic>=1) – none of which occurred in susceptible samples. We also found 13 pyrazinamide FN cases with a nonstop (stop–loss) mutation in <italic toggle="yes">pncA</italic>; this mutation type was also seen in 2 susceptible samples. Another <italic toggle="yes">pncA</italic> mutation, T100P, was also observed in 10 pyrazinamide FN samples and no susceptible samples. T100P only appears once in the WHO catalogue data (‘solo’ in a resistant sample). As such, it was given a grading of uncertain significance. As our dataset includes those samples in the WHO catalogue dataset, this means an additional nine isolates have been found with this mutation, indicating that this may warrant an upgrade to ‘associated with resistance’.</p>
      <p>We found an interesting case of allele combinations, where nine ethambutol FN samples have the same two <italic toggle="yes">embA</italic> mutations, c-12a and c-11a, and <italic toggle="yes">embB</italic> mutation P397T; this combination is only seen in two susceptible samples. Interestingly, <italic toggle="yes">embB</italic> P397T and <italic toggle="yes">embA</italic> c-12a do not appear in the WHO catalogue, but have been described as causing resistance previously [<xref rid="R59" ref-type="bibr">59</xref>]. Three <italic toggle="yes">katG</italic> mutations were also detected in isoniazid FN cases. First, G279D occurs in eight missed resistance samples and no susceptible cases. This mutation is graded as ‘uncertain significance’ in the WHO catalogue and was seen solo in four resistant samples in that data. Singh <italic toggle="yes">et al.</italic> performed a protein structural analysis caused by this mutation and found that it produced ‘an undesirable effect on the functionality of the protein’ [<xref rid="R60" ref-type="bibr">60</xref>]. Second, G699E occurs in eight FN samples and no susceptible cases, but has a WHO grading of ‘uncertain significance’ based on six resistant isolates; thus, we add two extra samples to that count. And third, N138H occurs in 14 FN samples and 1 susceptible sample. In seven of these cases, it co-occurs with <italic toggle="yes">ahpC</italic> mutations t-75g (<italic toggle="yes">n</italic>=2) and t-76a (<italic toggle="yes">n</italic>=5). This mutation only occurs in 3 resistant isolates in the WHO catalogue dataset, giving it an uncertain significance, but we add a further 11 cases. This mutation has been found to cause a high isoniazid MIC and to be associated with resistance [<xref rid="R61" ref-type="bibr">61, 62</xref>].</p>
    </sec>
    <sec id="s5-3">
      <title>Detection of large deletions</title>
      <p>There are expert rules in the WHO catalogue that treat gene loss of function (any frameshift or nonsense mutation) in <italic toggle="yes">katG</italic>, <italic toggle="yes">ethA</italic>, <italic toggle="yes">gid</italic> and <italic toggle="yes">pncA</italic> as causing resistance for isoniazid, ethionamide, streptomycin and pyrazinamide, respectively [<xref rid="R16" ref-type="bibr">16</xref>]. Although examples of resistance caused by gene deletion are rare [<xref rid="R63" ref-type="bibr">63–67</xref>], with a dataset of this size (<italic toggle="yes">n</italic>=44 709), we can both evaluate these rules and compare the detection power of DrPRG and TBProfiler for identifying gene deletions (Mykrobe does not, although in principle it could). In total we found 206 samples where DrPRG and/or TBProfiler identified deletions of <italic toggle="yes">ethA</italic>, <italic toggle="yes">katG</italic>, or <italic toggle="yes">pncA</italic>. Although many of these isolates did not have phenotype information for the associated drug (<italic toggle="yes">n</italic>=100), the results are nevertheless striking (<xref rid="F4" ref-type="fig">Fig. 4</xref>). Given the low false-positive rate of Pandora for gene absence detection [<xref rid="R11" ref-type="bibr">11</xref>], these no-phenotype samples provide insight into how often gene deletions are occurring in clinical samples.</p>
      <fig position="float" fig-type="figure" id="F4">
        <label>Fig. 4.</label>
        <caption>
          <p>Impact of gene deletion on resistance classification. The title of each subplot indicates the gene and drug it effects. Bars are coloured by their classification and stratified by tool. Count (<italic toggle="yes">y</italic>-axis) indicates the number of gene deletions for that category. The NA bar (white with diagonal lines) indicates the number of samples with that gene deleted but no phenotype information for the respective drug. TP true positive; FN, false negative; TN, true negative; FP, false positive; NA, no phenotype available.</p>
        </caption>
        <graphic xlink:href="mgen-9-1081-g004" position="float"/>
      </fig>
      <p>Of the 34 isolates where <italic toggle="yes">katG</italic> was identified as being absent, and an isoniazid phenotype was available, all 34 were phenotypically resistant. DrPRG detected all 34 (100 % sensitivity) and TBProfiler identified 26 (76.5 % sensitivity). Deletions of <italic toggle="yes">pncA</italic> were detected in 56 isolates, of which 49 were phenotypically resistant. DrPRG detected 47 (95.9 % sensitivity) and TBProfiler detected 46 (93.9 % sensitivity). Lastly, <italic toggle="yes">ethA</italic> was found to be missing in 16 samples with an ethionamide phenotype, of which 10 were phenotypically resistant. Both DrPRG and TBProfiler correctly predicted all 10 (100 % sensitivity). No <italic toggle="yes">gid</italic> deletions were discovered. We note that the TP calls made by Mykrobe were due to it detecting large deletions that are present in the catalogue, which is understandable given that the whole gene is deleted.</p>
      <p>We conclude that DrPRG is slightly more sensitive at detecting large deletions than TBProfiler (and Mykrobe) for <italic toggle="yes">katG</italic>, and equivalent for <italic toggle="yes">pncA</italic> and <italic toggle="yes">ethA.</italic> However, we note that the WHO expert rule, which predicts resistance to isolates missing specific genes, appears to be more accurate for <italic toggle="yes">katG</italic> (100 % of isolates missing the gene are resistant) than for <italic toggle="yes">pncA</italic> (87 % resistant) and <italic toggle="yes">ethA</italic> (62.5 % resistant).</p>
    </sec>
    <sec id="s5-4">
      <title>Runtime and memory usage benchmark</title>
      <p>The runtime and peak memory usage of each program was recorded for each sample and are presented in <xref rid="F5" ref-type="fig">Fig. 5</xref>. DrPRG (median 161 s) was significantly faster than both TBProfiler (307 s; <italic toggle="yes">P</italic>≤0.0001) and Mykrobe (230 s; <italic toggle="yes">P</italic>≤0.0001) with Illumina data. For Nanopore data, DrPRG (250 s) was significantly faster than TBProfiler (290 s; <italic toggle="yes">P</italic>≤0.0001), but significantly slower than Mykrobe (213 s; <italic toggle="yes">P</italic>=0.0347). In terms of peak memory usage, DrPRG (Illumina median peak memory 58 MB; Nanopore 277 MB) used significantly less memory than Mykrobe (1538 MB; 1538 MB) and TBProfiler (1463 MB; 1990 MB) for both Illumina and Nanopore data (<italic toggle="yes">P</italic>≤0.0001 for all comparisons).</p>
      <fig position="float" fig-type="figure" id="F5">
        <label>Fig. 5.</label>
        <caption>
          <p>Benchmark of the maximum memory usage (left panels) and runtime (right panels) for Illumina (upper row) and Nanopore (lower row) data. Each point and violin is coloured by the tool, with each point representing a single sample. Statistical annotations are the result of a Wilcoxon rank-sum paired data test on each pair of tools. Dashed lines inside the violins represent the quartiles of the distribution. Note, the <italic toggle="yes">x</italic>-axis is log-scaled.</p>
        </caption>
        <graphic xlink:href="mgen-9-1081-g005" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s6">
    <title>Discussion</title>
    <p>The dominant paradigm for analysing genetic variation relies on a central idea: all genomes in a species can be described as minor differences from a single reference genome. However, this approach can be problematic or inadequate for bacteria, where there can be significant sequence divergence within a species. Reference graphs are an emerging solution to the reference bias issues implicit in the ‘single-reference’ model [<xref rid="R11" ref-type="bibr">11, 68, 69</xref>]. Such a graph represents variation at multiple scales within a population – e.g. nucleotide and locus level. The graph structure used in Pandora is gene (or locus) oriented, and allows natural support or analysing SNP and indel mutations and the presence/absence of genes.</p>
    <p>In this work, we have presented a novel method for making drug resistance predictions with reference graphs. The method, DrPRG, requires only a reference genome and annotation, a catalogue of resistance-conferring mutations, a VCF of population variation from which to build a reference graph and (optionally) a set of rules for types of variants in specific genes that cause resistance. We apply DrPRG to the pathogen <italic toggle="yes"><named-content content-type="species"><ext-link xlink:href="http://doi.org/10.1601/nm.10886" ext-link-type="uri">M. tuberculosis</ext-link></named-content></italic>, for which there is a great deal of information on the genotype/phenotype relationship, and a great need to provide good tools that implement and augment current and forthcoming versions of the WHO catalogue. We illustrate the performance of DrPRG against two existing methods for drug resistance prediction – Mykrobe and TBProfiler.</p>
    <p>We benchmarked the methods on a high-quality Illumina sequencing dataset with associated phenotype profiles for 44 709 MTB genomes; the largest known dataset to date [<xref rid="R16" ref-type="bibr">16</xref>]. All tools used the same catalogue and rules, and for most drugs there was no significant difference between the tools. However, DrPRG did have a significantly higher specificity than TBProfiler for rifampicin predictions, and sensitivity for ethionamide predictions. DrPRG’s sensitivity was also significantly greater than Mykrobe’s for rifampicin, streptomycin, amikacin, capreomycin, kanamycin and ethionamide. Evaluating detection of gene loss, we found that DrPRG was more sensitive to <italic toggle="yes">katG</italic> deletions than TBProfiler.</p>
    <p>We also benchmarked using 138 Nanopore-sequenced MTB samples with phenotype information, but found no significant difference between the tools. This Nanopore dataset was quite small and therefore the confidence intervals were large for all drugs.</p>
    <p>DrPRG also used significantly less memory than Mykrobe and TBProfiler on both Nanopore and Illumina data. In addition, the runtime of DrPRG was significant faster than both tools for Illumina data and faster than TBProfiler for Nanopore data. While the absolute values for memory and runtime for all tools mean that they could all easily run on common computers found in the types of institutions likely to run them, the differences for the Nanopore data warrant noting. As Nanopore data can be generated ‘in the field’, computational resource usage is critical. For example, in a recent collaboration of ours with the National Tuberculosis programme in Madagascar [<xref rid="R27" ref-type="bibr">27</xref>], Nanopore sequencing and analysis are regularly performed on a laptop, meaning that memory usage is sometimes a limiting factor. DrPRG’s median peak memory was 277 MB, meaning that it can comfortably be run on any laptop or other mobile computing device [<xref rid="R70" ref-type="bibr">70</xref>].</p>
    <p>It is clear from the Illumina results that more work is needed to understand resistance-conferring mutations for delamanid and linezolid. However, we did find that nonsense mutations in the <italic toggle="yes">ddn</italic> gene appear likely to be resistance-conferring for delamanid – as has been noted previously [<xref rid="R39" ref-type="bibr">39, 71–73</xref>]. We also found a novel (likely) mechanism of resistance to pyrazinamide – a nonstop mutation in <italic toggle="yes">pncA</italic>. Phenotype instability in <italic toggle="yes">embB</italic> at codon 306 was also found to be the main driver in poor ethambutol specificity, as has been noted elsewhere [<xref rid="R54" ref-type="bibr">54, 55</xref>], indicating the need to further investigate cofactors that may influence the phenotype when mutations at this codon are present.</p>
    <p>Gene absence/deletion detection allowed us to confirm that the absence of <italic toggle="yes">katG</italic> – a mechanism that is rare in clinical samples [<xref rid="R63" ref-type="bibr">63–66, 74</xref>] – is highly likely to confer resistance to isoniazid. Additionally, we found that the absence of <italic toggle="yes">pncA</italic> is likely to cause resistance to pyrazinamide, as has been noted previously [<xref rid="R67" ref-type="bibr">67</xref>]. One finding that requires further investigation is the variability in ethionamide phenotype when <italic toggle="yes">ethA</italic> is absent. We found that only 63 % of the samples with <italic toggle="yes">ethA</italic> missing and an ethionamide phenotype were resistant. Ang <italic toggle="yes">et al.</italic> have suggested that <italic toggle="yes">ethA</italic> deletion alone does not always cause resistance and there might be an alternative pathway via <italic toggle="yes">mshA</italic> [<xref rid="R75" ref-type="bibr">75</xref>].</p>
    <p>Given the size of the Illumina dataset used in this work, the results provide a good marker of Illumina whole-genome sequencing’s ability to replace traditional phenotyping methods. With the catalogue used in this study, DrPRG meets the WHO’s target product profile for next-generation drug-susceptibility testing for both sensitivity and specificity for amikacin, and sensitivity only for rifampicin, isoniazid, levofloxacin and moxifloxacin. However, if we exclude cases where all tools call <italic toggle="yes">rpoB</italic> S450L or <italic toggle="yes">katG</italic> S315T for phenotypically susceptible samples (these are strong markers of resistance [<xref rid="R16" ref-type="bibr">16</xref>] and therefore we suspect sample swaps or phenotype error [<xref rid="R76" ref-type="bibr">76</xref>]), DrPRG also meets the specificity target product profile for rifampicin and isoniazid. For the other first-line drugs, ethambutol and pyrazinamide, ethambutol does not have a WHO target and DrPRG’s pyrazinamide sensitivity is 0.2 % below the WHO target (although the confidence interval spans the target), while the pyrazinamide specificity target is missed by 0.8 %.</p>
    <p>The primary limitation of the DrPRG method relates to minor allele calls. DrPRG uses Pandora for novel variant discovery, combining a graph of known population variants (which can be detected at low frequency) with <italic toggle="yes">de novo</italic> detection of other variants if present at above ~50 % frequency. Thus, it can miss minor allele calls if the allele is absent from its reference graph. While this issue did not impact on most drugs, it did account for the majority of cases where DrPRG missed pyrazinamide-resistant calls (in <italic toggle="yes">pncA</italic>), but the other tools correctly called resistance. Unlike most other genes, where there are a relatively small number of resistance-conferring mutations, or they are localized to a specific region (e.g. the rifampicin resistance-determining region in <italic toggle="yes">rpoB</italic>), resistance-conferring mutations are numerous – with most being rare – and distributed throughout <italic toggle="yes">pncA</italic> [<xref rid="R16" ref-type="bibr">16, 77, 78</xref>]. Adding all of these mutations leads to decreased performance of the reference graph (Section S3 and [<xref rid="R33" ref-type="bibr">33</xref>]), and so improving minor allele calling for pyrazinamide remains a challenge we need to revisit in the future.</p>
    <p>One final limitation is the small number of Nanopore-sequenced MTB isolates with phenotypic information. Increased Nanopore sequencing over time will provide better resolution of the overall sensitivity and specificity values and improve the methodological nuances of calling variants from this emerging, and continually changing, sequencing technology.</p>
    <p>In conclusion, DrPRG is a fast, memory-frugal software program for predicting drug resistance. We showed that on MTB it performs as well as, or better than, two other commonly used tools for resistance prediction. We also collected and curated the largest dataset of MTB Illumina-sequenced genomes with phenotype information and hope this will benefit future work to improved genotypic drug susceptibility testing for this species. While we applied DrPRG to MTB in this study, it is a framework that is agnostic to species. MTB is likely one of the bacterial species with the least to gain from reference graphs, given its relatively conserved (closed) pan-genome compared to other common species [<xref rid="R79" ref-type="bibr">79</xref>]. As such, we expect the benefits and performance of DrPRG to improve as the openness of the species’ pan-genome increases [<xref rid="R11" ref-type="bibr">11</xref>], especially given its good performance on a reasonably closed pan-genome.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Data</title>
    <supplementary-material position="float" id="supp1" content-type="local-data">
      <caption>
        <title>Supplementary material 1</title>
      </caption>
      <media xlink:href="mgen-9-1081-s001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Funding information</title>
    <p>M.B.H. and L.J.M.C. were supported by an Australian Government Medical Research Future Fund (MRFF) grant (2020/MRF1200856).</p>
  </ack>
  <ack id="ack2">
    <title>Acknowledgements</title>
    <p>We thank Kerri M. Malone for sharing her MTB knowledge through many discussions and critiquing the final manuscript. We also thank Martin Hunt and Jeff Knaggs for facilitating access to the CRyPTIC VCFs. Finally, we would like to acknowledge Timothy Walker for his clinically relevant MTB advice.</p>
  </ack>
  <ack id="ack3">
    <title>Author contributions</title>
    <p>M.B.H.: conceptualization, data curation, formal analysis, investigation, methodology, resources, software, visualization, writing – original draft, writing – review and editing. L.L.: resources, software, writing – review and editing. L.J.M.C.: funding acquisition, methodology, supervision, writing – review and editing. Z.I.: conceptualization, funding acquisition, methodology, supervision, writing – original draft, writing – review and editing.</p>
  </ack>
  <ack id="ack4">
    <title>Conflicts of interest</title>
    <p content-type="COI-statement">The authors declare that there are no conflicts of interest.</p>
  </ack>
  <fn-group>
    <fn id="fn1">
      <p>Abbreviations: DST, drug susceptibility testing; FN, false negative; FP, false positive; MIC, minimum inhibitory concentration; MTB, Mycobacterium tuberculosis; SNP, single nucleotide polymorphism; TB, tuberculosis; TN, true negative; TP, true positive; VCF, variant call format; WHO, world health organization.</p>
    </fn>
    <fn id="fn2">
      <p>All supporting data, code and protocols have been provided within the article or through supplementary data files.</p>
      <p>One supplementary material is available with the online version of this article.</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="R1">
      <label>1</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kurtzer</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Sochat</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Bauer</surname>
            <given-names>MW</given-names>
          </name>
        </person-group>
        <article-title>Singularity: scientific containers for mobility of compute</article-title>
        <source>PLoS One</source>
        <year>2017</year>
        <volume>12</volume>
        <elocation-id>e0177459</elocation-id>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0177459</pub-id>
        <?supplied-pmid 28494014?>
        <pub-id pub-id-type="pmid">28494014</pub-id>
      </element-citation>
    </ref>
    <ref id="R2">
      <label>2</label>
      <element-citation publication-type="journal">
        <person-group>
          <collab>Medical Research Council</collab>
        </person-group>
        <article-title>Streptomycin treatment of pulmonary tuberculosis: a medical research council Investigation</article-title>
        <source>BMJ</source>
        <year>1948</year>
        <volume>2</volume>
        <fpage>769</fpage>
        <lpage>782</lpage>
        <pub-id pub-id-type="doi">10.1136/bmj.2.4582.769</pub-id>
        <pub-id pub-id-type="pmid">18890300</pub-id>
      </element-citation>
    </ref>
    <ref id="R3">
      <label>3</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wengenack</surname>
            <given-names>NL</given-names>
          </name>
          <name>
            <surname>Todorovic</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Rusnak</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Evidence for differential binding of isoniazid by <italic toggle="yes">Mycobacterium tuberculosis</italic> KatG and the isoniazid-resistant mutant KatG(S315T)</article-title>
        <source>Biochemistry</source>
        <year>1998</year>
        <volume>37</volume>
        <fpage>15825</fpage>
        <lpage>15834</lpage>
        <pub-id pub-id-type="doi">10.1021/bi982023k</pub-id>
        <?supplied-pmid 9843388?>
        <pub-id pub-id-type="pmid">9843388</pub-id>
      </element-citation>
    </ref>
    <ref id="R4">
      <label>4</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hackbarth</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Kocagoz</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kocagoz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chambers</surname>
            <given-names>HF</given-names>
          </name>
        </person-group>
        <article-title>Point mutations in <italic toggle="yes">Staphylococcus aureus</italic> PBP 2 gene affect penicillin-binding kinetics and are associated with resistance</article-title>
        <source>Antimicrob Agents Chemother</source>
        <year>1995</year>
        <volume>39</volume>
        <fpage>103</fpage>
        <lpage>106</lpage>
        <pub-id pub-id-type="doi">10.1128/AAC.39.1.103</pub-id>
        <?supplied-pmid 7695289?>
        <pub-id pub-id-type="pmid">7695289</pub-id>
      </element-citation>
    </ref>
    <ref id="R5">
      <label>5</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Esposito</surname>
            <given-names>EP</given-names>
          </name>
          <name>
            <surname>Cervoni</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bernardo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Crivaro</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Cuccurullo</surname>
            <given-names>S</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Molecular epidemiology and virulence profiles of colistin-resistant <italic toggle="yes">Klebsiella pneumoniae</italic> blood isolates from the hospital agency “Ospedale dei Colli,” Naples, Italy</article-title>
        <source>Front Microbiol</source>
        <year>2018</year>
        <volume>9</volume>
        <fpage>1463</fpage>
        <pub-id pub-id-type="doi">10.3389/fmicb.2018.01463</pub-id>
        <?supplied-pmid 30061868?>
        <pub-id pub-id-type="pmid">30061868</pub-id>
      </element-citation>
    </ref>
    <ref id="R6">
      <label>6</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y-Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Walsh</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Yi</surname>
            <given-names>L-X</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>R</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study</article-title>
        <source>Lancet Infect Dis</source>
        <year>2016</year>
        <volume>16</volume>
        <fpage>161</fpage>
        <lpage>168</lpage>
        <pub-id pub-id-type="doi">10.1016/S1473-3099(15)00424-7</pub-id>
        <?supplied-pmid 26603172?>
        <pub-id pub-id-type="pmid">26603172</pub-id>
      </element-citation>
    </ref>
    <ref id="R7">
      <label>7</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Maira-Litrán</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Allison</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Gilbert</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>An evaluation of the potential of the multiple antibiotic resistance operon (mar) and the multidrug efflux pump acrAB to moderate resistance towards ciprofloxacin in <italic toggle="yes">Escherichia coli</italic> biofilms</article-title>
        <source>J Antimicrob Chemother</source>
        <year>2000</year>
        <volume>45</volume>
        <fpage>789</fpage>
        <lpage>795</lpage>
        <pub-id pub-id-type="doi">10.1093/jac/45.6.789</pub-id>
        <?supplied-pmid 10837431?>
        <pub-id pub-id-type="pmid">10837431</pub-id>
      </element-citation>
    </ref>
    <ref id="R8">
      <label>8</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Werngren</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sturegård</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Juréen</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ängeby</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hoffner</surname>
            <given-names>S</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Reevaluation of the critical concentration for drug susceptibility testing of <italic toggle="yes">Mycobacterium tuberculosis</italic> against pyrazinamide using wild-type MIC distributions and pncA gene sequencing</article-title>
        <source>Antimicrob Agents Chemother</source>
        <year>2012</year>
        <volume>56</volume>
        <fpage>1253</fpage>
        <lpage>1257</lpage>
        <pub-id pub-id-type="doi">10.1128/AAC.05894-11</pub-id>
        <?supplied-pmid 22203587?>
        <pub-id pub-id-type="pmid">22203587</pub-id>
      </element-citation>
    </ref>
    <ref id="R9">
      <label>9</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schön</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Miotto</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Köser</surname>
            <given-names>CU</given-names>
          </name>
          <name>
            <surname>Viveiros</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Böttger</surname>
            <given-names>E</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title><italic toggle="yes">Mycobacterium tuberculosis</italic> drug-resistance testing: challenges, recent developments and perspectives</article-title>
        <source>Clin Microbiol Infect</source>
        <year>2017</year>
        <volume>23</volume>
        <fpage>154</fpage>
        <lpage>160</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cmi.2016.10.022</pub-id>
        <?supplied-pmid 27810467?>
        <pub-id pub-id-type="pmid">27810467</pub-id>
      </element-citation>
    </ref>
    <ref id="R10">
      <label>10</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McInerney</surname>
            <given-names>JO</given-names>
          </name>
          <name>
            <surname>McNally</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>O’Connell</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>Why prokaryotes have pangenomes</article-title>
        <source>Nat Microbiol</source>
        <year>2017</year>
        <volume>2</volume>
        <fpage>17040</fpage>
        <pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.40</pub-id>
        <pub-id pub-id-type="pmid">28350002</pub-id>
      </element-citation>
    </ref>
    <ref id="R11">
      <label>11</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Colquhoun</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Lima</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>LW</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>KM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Pandora: nucleotide-resolution bacterial pan-genomics with reference graphs</article-title>
        <source>Genome Biol</source>
        <year>2021</year>
        <volume>22</volume>
        <elocation-id>267</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s13059-021-02473-1</pub-id>
        <?supplied-pmid 34521456?>
        <pub-id pub-id-type="pmid">34521456</pub-id>
      </element-citation>
    </ref>
    <ref id="R12">
      <label>12</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hall</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Coin</surname>
            <given-names>LJM</given-names>
          </name>
        </person-group>
        <article-title>Assessment of the 2021 WHO <italic toggle="yes">Mycobacterium tuberculosis</italic> drug resistance mutation catalogue on an independent dataset</article-title>
        <source>Lancet Microbe</source>
        <year>2022</year>
        <volume>3</volume>
        <elocation-id>e645</elocation-id>
        <pub-id pub-id-type="doi">10.1016/S2666-5247(22)00151-3</pub-id>
        <?supplied-pmid 35659881?>
        <pub-id pub-id-type="pmid">35659881</pub-id>
      </element-citation>
    </ref>
    <ref id="R13">
      <label>13</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mahfouz</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ferreira</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Beisken</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>von Haeseler</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Posch</surname>
            <given-names>AE</given-names>
          </name>
        </person-group>
        <article-title>Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review</article-title>
        <source>J Antimicrob Chemother</source>
        <year>2020</year>
        <volume>75</volume>
        <fpage>3099</fpage>
        <lpage>3108</lpage>
        <pub-id pub-id-type="doi">10.1093/jac/dkaa257</pub-id>
        <?supplied-pmid 32658975?>
        <pub-id pub-id-type="pmid">32658975</pub-id>
      </element-citation>
    </ref>
    <ref id="R14">
      <label>14</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hendriksen</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Bortolaia</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Tate</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Tyson</surname>
            <given-names>GH</given-names>
          </name>
          <name>
            <surname>Aarestrup</surname>
            <given-names>FM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Using genomics to track global antimicrobial resistance</article-title>
        <source>Front Public Health</source>
        <year>2019</year>
        <volume>7</volume>
        <fpage>242</fpage>
        <pub-id pub-id-type="doi">10.3389/fpubh.2019.00242</pub-id>
        <?supplied-pmid 31552211?>
        <pub-id pub-id-type="pmid">31552211</pub-id>
      </element-citation>
    </ref>
    <ref id="R15">
      <label>15</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Godfroid</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dagan</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kupczok</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Recombination signal in <italic toggle="yes">Mycobacterium tuberculosis</italic> stems from reference-guided assemblies and alignment artefacts</article-title>
        <source>Genome Biol Evol</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>1920</fpage>
        <lpage>1926</lpage>
        <pub-id pub-id-type="doi">10.1093/gbe/evy143</pub-id>
        <?supplied-pmid 30010866?>
        <pub-id pub-id-type="pmid">30010866</pub-id>
      </element-citation>
    </ref>
    <ref id="R16">
      <label>16</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Walker</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Miotto</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Köser</surname>
            <given-names>CU</given-names>
          </name>
          <name>
            <surname>Fowler</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Knaggs</surname>
            <given-names>J</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>The 2021 WHO catalogue of <italic toggle="yes">Mycobacterium tuberculosis</italic> complex mutations associated with drug resistance: a genotypic analysis</article-title>
        <source>Lancet Microbe</source>
        <year>2022</year>
        <volume>3</volume>
        <fpage>e265</fpage>
        <lpage>e273</lpage>
        <pub-id pub-id-type="doi">10.1016/S2666-5247(21)00301-3</pub-id>
        <?supplied-pmid 35373160?>
        <pub-id pub-id-type="pmid">35373160</pub-id>
      </element-citation>
    </ref>
    <ref id="R17">
      <label>17</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Votintseva</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Bradley</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pankhurst</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Del Ojo Elias</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Loose</surname>
            <given-names>M</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples</article-title>
        <source>J Clin Microbiol</source>
        <year>2017</year>
        <volume>55</volume>
        <fpage>1285</fpage>
        <lpage>1298</lpage>
        <pub-id pub-id-type="doi">10.1128/JCM.02483-16</pub-id>
        <?supplied-pmid 28275074?>
        <pub-id pub-id-type="pmid">28275074</pub-id>
      </element-citation>
    </ref>
    <ref id="R18">
      <label>18</label>
      <element-citation publication-type="book">
        <person-group>
          <collab>The end TB strategy</collab>
        </person-group>
        <article-title>Report No.: WHO/HTM/TB/2015.19. Available</article-title>
        <publisher-name>Geneva: World Health Organization</publisher-name>
        <year>2015</year>
        <ext-link xlink:href="https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19" ext-link-type="uri">https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19</ext-link>
      </element-citation>
    </ref>
    <ref id="R19">
      <label>19</label>
      <element-citation publication-type="book">
        <article-title>Target product profile for next-generation drug-susceptibility testing at peripheral centres</article-title>
        <publisher-name>Geneva: World Health Organization</publisher-name>
        <year>2021</year>
        <ext-link xlink:href="https://www.who.int/publications/i/item/9789240032361" ext-link-type="uri">https://www.who.int/publications/i/item/9789240032361</ext-link>
      </element-citation>
    </ref>
    <ref id="R20">
      <label>20</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>MacLean</surname>
            <given-names>EL-H</given-names>
          </name>
          <name>
            <surname>Miotto</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>González Angulo</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chiacchiaretta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>TM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Updating the WHO target product profile for next-generation <italic toggle="yes">Mycobacterium tuberculosis</italic> drug susceptibility testing at peripheral centres</article-title>
        <source>PLoS Glob Public Health</source>
        <year>2023</year>
        <volume>3</volume>
        <elocation-id>e0001754</elocation-id>
        <pub-id pub-id-type="doi">10.1371/journal.pgph.0001754</pub-id>
        <?supplied-pmid 37000774?>
        <pub-id pub-id-type="pmid">37000774</pub-id>
      </element-citation>
    </ref>
    <ref id="R21">
      <label>21</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Steiner</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stucki</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Coscolla</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Borrell</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gagneux</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes</article-title>
        <source>BMC Genomics</source>
        <year>2014</year>
        <volume>15</volume>
        <elocation-id>881</elocation-id>
        <pub-id pub-id-type="doi">10.1186/1471-2164-15-881</pub-id>
        <?supplied-pmid 25297886?>
        <pub-id pub-id-type="pmid">25297886</pub-id>
      </element-citation>
    </ref>
    <ref id="R22">
      <label>22</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Phelan</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>O’Sullivan</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Machado</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ramos</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Oppong</surname>
            <given-names>YEA</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs</article-title>
        <source>Genome Med</source>
        <year>2019</year>
        <volume>11</volume>
        <elocation-id>41</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s13073-019-0650-x</pub-id>
        <?supplied-pmid 31234910?>
        <pub-id pub-id-type="pmid">31234910</pub-id>
      </element-citation>
    </ref>
    <ref id="R23">
      <label>23</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bradley</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gordon</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Walker</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Dunn</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Heys</surname>
            <given-names>S</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Rapid antibiotic-resistance predictions from genome sequence data for <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>Nat Commun</source>
        <year>2015</year>
        <volume>6</volume>
        <elocation-id>10063</elocation-id>
        <pub-id pub-id-type="doi">10.1038/ncomms10063</pub-id>
        <?supplied-pmid 26686880?>
        <pub-id pub-id-type="pmid">26686880</pub-id>
      </element-citation>
    </ref>
    <ref id="R24">
      <label>24</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kohl</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Utpatel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schleusener</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>De Filippo</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Beckert</surname>
            <given-names>P</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>MTBseq: a comprehensive pipeline for whole genome sequence analysis of <italic toggle="yes">Mycobacterium tuberculosis</italic> complex isolates</article-title>
        <source>PeerJ</source>
        <year>2018</year>
        <volume>6</volume>
        <elocation-id>e5895</elocation-id>
        <pub-id pub-id-type="doi">10.7717/peerj.5895</pub-id>
        <?supplied-pmid 30479891?>
        <pub-id pub-id-type="pmid">30479891</pub-id>
      </element-citation>
    </ref>
    <ref id="R25">
      <label>25</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Feuerriegel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schleusener</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Beckert</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kohl</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Miotto</surname>
            <given-names>P</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>PhyResSE: a web tool delineating <italic toggle="yes">Mycobacterium tuberculosis</italic> antibiotic resistance and lineage from whole-genome sequencing data</article-title>
        <source>J Clin Microbiol</source>
        <year>2015</year>
        <volume>53</volume>
        <fpage>1908</fpage>
        <lpage>1914</lpage>
        <pub-id pub-id-type="doi">10.1128/JCM.00025-15</pub-id>
        <pub-id pub-id-type="pmid">25854485</pub-id>
      </element-citation>
    </ref>
    <ref id="R26">
      <label>26</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hunt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bradley</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Lapierre</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Heys</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Thomsit</surname>
            <given-names>M</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Antibiotic resistance prediction for <italic toggle="yes">Mycobacterium tuberculosis</italic> from genome sequence data with Mykrobe</article-title>
        <source>Wellcome Open Res</source>
        <year>2019</year>
        <volume>4</volume>
        <elocation-id>191</elocation-id>
        <pub-id pub-id-type="doi">10.12688/wellcomeopenres.15603.1</pub-id>
        <?supplied-pmid 32055708?>
        <pub-id pub-id-type="pmid">32055708</pub-id>
      </element-citation>
    </ref>
    <ref id="R27">
      <label>27</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hall</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Rabodoarivelo</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Koch</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dippenaar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>George</surname>
            <given-names>S</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Evaluation of Nanopore sequencing for <italic toggle="yes">Mycobacterium tuberculosis</italic> drug susceptibility testing and outbreak investigation: a genomic analysis</article-title>
        <source>Lancet Microbe</source>
        <year>2023</year>
        <volume>4</volume>
        <fpage>e84</fpage>
        <lpage>e92</lpage>
        <pub-id pub-id-type="doi">10.1016/S2666-5247(22)00301-9</pub-id>
        <?supplied-pmid 36549315?>
        <pub-id pub-id-type="pmid">36549315</pub-id>
      </element-citation>
    </ref>
    <ref id="R28">
      <label>28</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garrison</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Marth</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Haplotype-based variant detection from short-read sequencing</article-title>
        <source>arXiv</source>
        <year>2012</year>
        <pub-id pub-id-type="doi">10.48550/arXiv.1207.3907</pub-id>
      </element-citation>
    </ref>
    <ref id="R29">
      <label>29</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rausch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zichner</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Schlattl</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stütz</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Benes</surname>
            <given-names>V</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>DELLY: structural variant discovery by integrated paired-end and split-read analysis</article-title>
        <source>Bioinformatics</source>
        <year>2012</year>
        <volume>28</volume>
        <fpage>i333</fpage>
        <lpage>i339</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bts378</pub-id>
        <?supplied-pmid 22962449?>
        <pub-id pub-id-type="pmid">22962449</pub-id>
      </element-citation>
    </ref>
    <ref id="R30">
      <label>30</label>
      <element-citation publication-type="journal">
        <person-group>
          <collab>The CRyPTIC Consortium</collab>
          <name>
            <surname>Ladner</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>A data compendium associating the genomes of 12,289 <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates with quantitative resistance phenotypes to 13 antibiotics</article-title>
        <source>PLoS Biol</source>
        <year>2022</year>
        <volume>20</volume>
        <elocation-id>e3001721</elocation-id>
        <pub-id pub-id-type="doi">10.1371/journal.pbio.3001721</pub-id>
        <pub-id pub-id-type="pmid">35944069</pub-id>
      </element-citation>
    </ref>
    <ref id="R31">
      <label>31</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chiner-Oms</surname>
            <given-names>Á</given-names>
          </name>
          <name>
            <surname>Berney</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Boinett</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>González-Candelas</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>DB</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Genome-wide mutational biases fuel transcriptional diversity in the <italic toggle="yes">Mycobacterium tuberculosis</italic> complex</article-title>
        <source>Nat Commun</source>
        <year>2019</year>
        <volume>10</volume>
        <elocation-id>3994</elocation-id>
        <pub-id pub-id-type="doi">10.1038/s41467-019-11948-6</pub-id>
        <?supplied-pmid 31488832?>
        <pub-id pub-id-type="pmid">31488832</pub-id>
      </element-citation>
    </ref>
    <ref id="R32">
      <label>32</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Letcher</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hunt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Iqbal</surname>
            <given-names>Z</given-names>
          </name>
        </person-group>
        <article-title>Gramtools enables multiscale variation analysis with genome graphs</article-title>
        <source>Genome Biol</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>259</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-021-02474-0</pub-id>
        <pub-id pub-id-type="pmid">34488837</pub-id>
      </element-citation>
    </ref>
    <ref id="R33">
      <label>33</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pritt</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>N-C</given-names>
          </name>
          <name>
            <surname>Langmead</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>FORGe: prioritizing variants for graph genomes</article-title>
        <source>Genome Biol</source>
        <year>2018</year>
        <volume>19</volume>
        <elocation-id>220</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s13059-018-1595-x</pub-id>
        <?supplied-pmid 30558649?>
        <pub-id pub-id-type="pmid">30558649</pub-id>
      </element-citation>
    </ref>
    <ref id="R34">
      <label>34</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Katoh</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Frith</surname>
            <given-names>MC</given-names>
          </name>
        </person-group>
        <article-title>Adding unaligned sequences into an existing alignment using MAFFT and LAST</article-title>
        <source>Bioinformatics</source>
        <year>2012</year>
        <volume>28</volume>
        <fpage>3144</fpage>
        <lpage>3146</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bts578</pub-id>
        <?supplied-pmid 23023983?>
        <pub-id pub-id-type="pmid">23023983</pub-id>
      </element-citation>
    </ref>
    <ref id="R35">
      <label>35</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Katoh</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Misawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kuma</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Miyata</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform</article-title>
        <source>Nucleic Acids Res</source>
        <year>2002</year>
        <volume>30</volume>
        <fpage>3059</fpage>
        <lpage>3066</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkf436</pub-id>
        <?supplied-pmid 12136088?>
        <pub-id pub-id-type="pmid">12136088</pub-id>
      </element-citation>
    </ref>
    <ref id="R36">
      <label>36</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mölder</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Jablonski</surname>
            <given-names>KP</given-names>
          </name>
          <name>
            <surname>Letcher</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Tomkins-Tinch</surname>
            <given-names>CH</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Sustainable data analysis with Snakemake</article-title>
        <source>F1000Res</source>
        <year>2021</year>
        <volume>10</volume>
        <fpage>33</fpage>
        <pub-id pub-id-type="doi">10.12688/f1000research.29032.2</pub-id>
        <?supplied-pmid 34035898?>
        <pub-id pub-id-type="pmid">34035898</pub-id>
      </element-citation>
    </ref>
    <ref id="R37">
      <label>37</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gröschel</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Owens</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Freschi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Vargas</surname>
            <given-names>R</given-names>
            <suffix>Jr</suffix>
          </name>
          <name>
            <surname>Marin</surname>
            <given-names>MG</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>GenTB: a user-friendly genome-based predictor for tuberculosis resistance powered by machine learning</article-title>
        <source>Genome Med</source>
        <year>2021</year>
        <volume>13</volume>
        <elocation-id>138</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s13073-021-00953-4</pub-id>
        <?supplied-pmid 34461978?>
        <pub-id pub-id-type="pmid">34461978</pub-id>
      </element-citation>
    </ref>
    <ref id="R38">
      <label>38</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Trisakul</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nonghanphithak</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chaiyachat</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kaewprasert</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Sakmongkoljit</surname>
            <given-names>K</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates</article-title>
        <source>Emerg Microbes Infect</source>
        <year>2022</year>
        <volume>11</volume>
        <fpage>1857</fpage>
        <lpage>1866</lpage>
        <pub-id pub-id-type="doi">10.1080/22221751.2022.2099304</pub-id>
        <?supplied-pmid 35792049?>
        <pub-id pub-id-type="pmid">35792049</pub-id>
      </element-citation>
    </ref>
    <ref id="R39">
      <label>39</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Battaglia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Spitaleri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cabibbe</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Meehan</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Utpatel</surname>
            <given-names>C</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Characterization of genomic variants associated with resistance to bedaquiline and delamanid in naive <italic toggle="yes">Mycobacterium tuberculosis</italic> clinical strains</article-title>
        <source>J Clin Microbiol</source>
        <year>2020</year>
        <volume>58</volume>
        <elocation-id>e01304-20</elocation-id>
        <pub-id pub-id-type="doi">10.1128/JCM.01304-20</pub-id>
        <?supplied-pmid 32907992?>
        <pub-id pub-id-type="pmid">32907992</pub-id>
      </element-citation>
    </ref>
    <ref id="R40">
      <label>40</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>X</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Cross-sectional whole-genome sequencing and epidemiological study of multidrug-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic> in China</article-title>
        <source>Clin Infect Dis</source>
        <year>2019</year>
        <volume>69</volume>
        <fpage>405</fpage>
        <lpage>413</lpage>
        <pub-id pub-id-type="doi">10.1093/cid/ciy883</pub-id>
        <?supplied-pmid 30321294?>
        <pub-id pub-id-type="pmid">30321294</pub-id>
      </element-citation>
    </ref>
    <ref id="R41">
      <label>41</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bainomugisa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lavu</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Hiashiri</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Majumdar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Honjepari</surname>
            <given-names>A</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic> in a high-prevalence setting of Papua New Guinea for over three decades</article-title>
        <source>Microbial Genomics</source>
        <year>2018</year>
        <volume>4</volume>
        <elocation-id>e000147</elocation-id>
        <pub-id pub-id-type="doi">10.1099/mgen.0.000147</pub-id>
        <pub-id pub-id-type="pmid">29310751</pub-id>
      </element-citation>
    </ref>
    <ref id="R42">
      <label>42</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Halse</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Shea</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Modestil</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Fowler</surname>
            <given-names>RC</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Assessing nanopore sequencing for clinical diagnostics: a comparison of Next-Generation Sequencing (NGS) methods for <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>J Clin Microbiol</source>
        <year>2020</year>
        <volume>59</volume>
        <elocation-id>e00583-20</elocation-id>
        <pub-id pub-id-type="doi">10.1128/JCM.00583-20</pub-id>
        <?supplied-pmid 33055186?>
        <pub-id pub-id-type="pmid">33055186</pub-id>
      </element-citation>
    </ref>
    <ref id="R43">
      <label>43</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Peker</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Schuele</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Kok</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Terrazos</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Neuenschwander</surname>
            <given-names>SM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Evaluation of whole-genome sequence data analysis approaches for short- and long-read sequencing of <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>Microbial Genomics</source>
        <year>2021</year>
        <volume>7</volume>
        <pub-id pub-id-type="doi">10.1099/mgen.0.000695</pub-id>
      </element-citation>
    </ref>
    <ref id="R44">
      <label>44</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Merker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rasigade</surname>
            <given-names>J-P</given-names>
          </name>
          <name>
            <surname>Barbier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cox</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Feuerriegel</surname>
            <given-names>S</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Transcontinental spread and evolution of <italic toggle="yes">Mycobacterium tuberculosis</italic> W148 European/Russian clade toward extensively drug resistant tuberculosis</article-title>
        <source>Nat Commun</source>
        <year>2022</year>
        <volume>13</volume>
        <elocation-id>5105</elocation-id>
        <pub-id pub-id-type="doi">10.1038/s41467-022-32455-1</pub-id>
        <?supplied-pmid 36042200?>
        <pub-id pub-id-type="pmid">36042200</pub-id>
      </element-citation>
    </ref>
    <ref id="R45">
      <label>45</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Finci</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Albertini</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Merker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Andres</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bablishvili</surname>
            <given-names>N</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Investigating resistance in clinical <italic toggle="yes">Mycobacterium tuberculosis</italic> complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study</article-title>
        <source>Lancet Microbe</source>
        <year>2022</year>
        <volume>3</volume>
        <fpage>e672</fpage>
        <lpage>e682</lpage>
        <pub-id pub-id-type="doi">10.1016/S2666-5247(22)00116-1</pub-id>
        <?supplied-pmid 35907429?>
        <pub-id pub-id-type="pmid">35907429</pub-id>
      </element-citation>
    </ref>
    <ref id="R46">
      <label>46</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Roberts</surname>
            <given-names>LW</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Hunt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Joseph</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wintringer</surname>
            <given-names>P</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Repeated evolution of bedaquiline resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic> is driven by truncation of mmpR5</article-title>
        <source>Microbiology</source>
        <year>2022</year>
        <pub-id pub-id-type="doi">10.1101/2022.12.08.519610</pub-id>
      </element-citation>
    </ref>
    <ref id="R47">
      <label>47</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Di Marco</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Spitaleri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Battaglia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Batignani</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Cabibbe</surname>
            <given-names>AM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Advantages of long- and short-reads sequencing for the hybrid investigation of the <italic toggle="yes">Mycobacterium tuberculosis</italic> genome</article-title>
        <source>Front Microbiol</source>
        <year>2023</year>
        <volume>14</volume>
        <elocation-id>1104456</elocation-id>
        <pub-id pub-id-type="doi">10.3389/fmicb.2023.1104456</pub-id>
        <?supplied-pmid 36819039?>
        <pub-id pub-id-type="pmid">36819039</pub-id>
      </element-citation>
    </ref>
    <ref id="R48">
      <label>48</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lempens</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Decroo</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Aung</surname>
            <given-names>KJM</given-names>
          </name>
          <name>
            <surname>Hossain</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Rigouts</surname>
            <given-names>L</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen</article-title>
        <source>Int J Infect Dis</source>
        <year>2020</year>
        <volume>100</volume>
        <fpage>357</fpage>
        <lpage>365</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ijid.2020.08.042</pub-id>
        <?supplied-pmid 32829049?>
        <pub-id pub-id-type="pmid">32829049</pub-id>
      </element-citation>
    </ref>
    <ref id="R49">
      <label>49</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lempens</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Meehan</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Vandelannoote</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Fissette</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>de Rijk</surname>
            <given-names>P</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Isoniazid resistance levels of <italic toggle="yes">Mycobacterium tuberculosis</italic> can largely be predicted by high-confidence resistance-conferring mutations</article-title>
        <source>Sci Rep</source>
        <year>2018</year>
        <volume>8</volume>
        <elocation-id>3246</elocation-id>
        <pub-id pub-id-type="doi">10.1038/s41598-018-21378-x</pub-id>
        <?supplied-pmid 29459669?>
        <pub-id pub-id-type="pmid">29459669</pub-id>
      </element-citation>
    </ref>
    <ref id="R50">
      <label>50</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Steinig</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Coin</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Nanoq: ultra-fast quality control for nanopore reads</article-title>
        <source>J Open Source Softw</source>
        <year>2022</year>
        <volume>7</volume>
        <fpage>2991</fpage>
        <pub-id pub-id-type="doi">10.21105/joss.02991</pub-id>
      </element-citation>
    </ref>
    <ref id="R51">
      <label>51</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>fastp: an ultra-fast all-in-one FASTQ preprocessor</article-title>
        <source>Bioinformatics</source>
        <year>2018</year>
        <volume>34</volume>
        <fpage>i884</fpage>
        <lpage>i890</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty560</pub-id>
        <?supplied-pmid 30423086?>
        <pub-id pub-id-type="pmid">30423086</pub-id>
      </element-citation>
    </ref>
    <ref id="R52">
      <label>52</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hunt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Letcher</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>MB</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Minos: variant adjudication and joint genotyping of cohorts of bacterial genomes</article-title>
        <source>Genome Biol</source>
        <year>2022</year>
        <volume>23</volume>
        <elocation-id>147</elocation-id>
        <pub-id pub-id-type="doi">10.1186/s13059-022-02714-x</pub-id>
        <?supplied-pmid 35791022?>
        <pub-id pub-id-type="pmid">35791022</pub-id>
      </element-citation>
    </ref>
    <ref id="R53">
      <label>53</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Virtanen</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gommers</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Oliphant</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Haberland</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Reddy</surname>
            <given-names>T</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Author Correction: SciPy 1.0: fundamental algorithms for scientific computing in Python</article-title>
        <source>Nat Methods</source>
        <year>2020</year>
        <volume>17</volume>
        <fpage>261</fpage>
        <lpage>272</lpage>
        <pub-id pub-id-type="doi">10.1038/s41592-020-0772-5</pub-id>
        <?supplied-pmid 32094914?>
        <pub-id pub-id-type="pmid">32015543</pub-id>
      </element-citation>
    </ref>
    <ref id="R54">
      <label>54</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Takiff</surname>
            <given-names>HE</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>Phenotypic instability of <italic toggle="yes">Mycobacterium tuberculosis</italic> strains harbouring clinically prevalent drug-resistant mutations</article-title>
        <source>Lancet Microbe</source>
        <year>2023</year>
        <volume>4</volume>
        <elocation-id>e292</elocation-id>
        <pub-id pub-id-type="doi">10.1016/S2666-5247(23)00007-1</pub-id>
        <?supplied-pmid 36716755?>
        <pub-id pub-id-type="pmid">36716755</pub-id>
      </element-citation>
    </ref>
    <ref id="R55">
      <label>55</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sirgel</surname>
            <given-names>FA</given-names>
          </name>
          <name>
            <surname>Warren</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Streicher</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Victor</surname>
            <given-names>TC</given-names>
          </name>
          <name>
            <surname>van Helden</surname>
            <given-names>PD</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>embB306 mutations as molecular indicators to predict ethambutol susceptibility in <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>Chemotherapy</source>
        <year>2012</year>
        <volume>58</volume>
        <fpage>358</fpage>
        <lpage>363</lpage>
        <pub-id pub-id-type="doi">10.1159/000343474</pub-id>
        <?supplied-pmid 23171739?>
        <pub-id pub-id-type="pmid">23171739</pub-id>
      </element-citation>
    </ref>
    <ref id="R56">
      <label>56</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huo</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Xue</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Shang</surname>
            <given-names>Y</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Specific gyrA gene mutations correlate with high prevalence of discordant levofloxacin resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates from Beijing, China</article-title>
        <source>J Mol Diagn</source>
        <year>2020</year>
        <volume>22</volume>
        <fpage>1199</fpage>
        <lpage>1204</lpage>
        <pub-id pub-id-type="doi">10.1016/j.jmoldx.2020.06.010</pub-id>
        <?supplied-pmid 32619641?>
        <pub-id pub-id-type="pmid">32619641</pub-id>
      </element-citation>
    </ref>
    <ref id="R57">
      <label>57</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brankin</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Fowler</surname>
            <given-names>PW</given-names>
          </name>
        </person-group>
        <article-title>Inclusion of minor alleles improves catalogue-based prediction of fluoroquinolone resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>JAC Antimicrob Resist</source>
        <year>2023</year>
        <volume>5</volume>
        <elocation-id>dlad039</elocation-id>
        <pub-id pub-id-type="doi">10.1093/jacamr/dlad039</pub-id>
        <?supplied-pmid 37025302?>
        <pub-id pub-id-type="pmid">37025302</pub-id>
      </element-citation>
    </ref>
    <ref id="R58">
      <label>58</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nimmo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Brien</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Millard</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Grant</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Padayatchi</surname>
            <given-names>N</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Dynamics of within-host <italic toggle="yes">Mycobacterium tuberculosis</italic> diversity and heteroresistance during treatment</article-title>
        <source>EBioMedicine</source>
        <year>2020</year>
        <volume>55</volume>
        <elocation-id>102747</elocation-id>
        <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102747</pub-id>
        <?supplied-pmid 32361247?>
        <pub-id pub-id-type="pmid">32361247</pub-id>
      </element-citation>
    </ref>
    <ref id="R59">
      <label>59</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Perdigão</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gomes</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Miranda</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Maltez</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Machado</surname>
            <given-names>D</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Using genomics to understand the origin and dispersion of multidrug and extensively drug resistant tuberculosis in Portugal</article-title>
        <source>Sci Rep</source>
        <year>2020</year>
        <volume>10</volume>
        <fpage>2600</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-020-59558-3</pub-id>
        <pub-id pub-id-type="pmid">32054988</pub-id>
      </element-citation>
    </ref>
    <ref id="R60">
      <label>60</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Grover</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pandey</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kumari</surname>
            <given-names>A</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Wild-type catalase peroxidase vs G279D mutant type: Molecular basis of Isoniazid drug resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>Gene</source>
        <year>2018</year>
        <volume>641</volume>
        <fpage>226</fpage>
        <lpage>234</lpage>
        <pub-id pub-id-type="doi">10.1016/j.gene.2017.10.047</pub-id>
        <?supplied-pmid 29066301?>
        <pub-id pub-id-type="pmid">29066301</pub-id>
      </element-citation>
    </ref>
    <ref id="R61">
      <label>61</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vaziri</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kohl</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Ghajavand</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kargarpour Kamakoli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Merker</surname>
            <given-names>M</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Genetic diversity of multi- and extensively drug-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates in the Capital of Iran, revealed by whole-genome sequencing</article-title>
        <source>J Clin Microbiol</source>
        <year>2019</year>
        <volume>57</volume>
        <elocation-id>e01477-18</elocation-id>
        <pub-id pub-id-type="doi">10.1128/JCM.01477-18</pub-id>
        <?supplied-pmid 30404943?>
        <pub-id pub-id-type="pmid">30404943</pub-id>
      </element-citation>
    </ref>
    <ref id="R62">
      <label>62</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>de Lourdes do Carmo Guimarães Diniz</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>von Groll</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Unis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Dalla-Costa</surname>
            <given-names>ER</given-names>
          </name>
          <name>
            <surname>Rosa Rossetti</surname>
            <given-names>ML</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Whole-genome sequencing as a tool for studying the microevolution of drug-resistant serial <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates</article-title>
        <source>Tuberculosis</source>
        <year>2021</year>
        <volume>131</volume>
        <fpage>102137</fpage>
        <pub-id pub-id-type="doi">10.1016/j.tube.2021.102137</pub-id>
        <?supplied-pmid 34673379?>
        <pub-id pub-id-type="pmid">34673379</pub-id>
      </element-citation>
    </ref>
    <ref id="R63">
      <label>63</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Altamirano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Marostenmaki</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>FitzGerald</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Black</surname>
            <given-names>WA</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Mutations in the catalase-peroxidase gene from isoniazid-resistant <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates</article-title>
        <source>J Infect Dis</source>
        <year>1994</year>
        <volume>169</volume>
        <fpage>1162</fpage>
        <lpage>1165</lpage>
        <pub-id pub-id-type="doi">10.1093/infdis/169.5.1162</pub-id>
        <?supplied-pmid 8169415?>
        <pub-id pub-id-type="pmid">8169415</pub-id>
      </element-citation>
    </ref>
    <ref id="R64">
      <label>64</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferrazoli</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Palaci</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Telles</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Ueki</surname>
            <given-names>SY</given-names>
          </name>
          <name>
            <surname>Kritski</surname>
            <given-names>A</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Catalase expression, katG, and MIC of isoniazid for <italic toggle="yes">Mycobacterium tuberculosis</italic> isolates from SãO Paulo, Brazil</article-title>
        <source>J Infect Dis</source>
        <year>1995</year>
        <volume>171</volume>
        <fpage>237</fpage>
        <lpage>240</lpage>
        <pub-id pub-id-type="doi">10.1093/infdis/171.1.237</pub-id>
        <?supplied-pmid 7798672?>
        <pub-id pub-id-type="pmid">7798672</pub-id>
      </element-citation>
    </ref>
    <ref id="R65">
      <label>65</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ramaswamy</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Reich</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>S-J</given-names>
          </name>
          <name>
            <surname>Jasperse</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>X</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Single nucleotide polymorphisms in genes associated with isoniazid resistance in <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>Antimicrob Agents Chemother</source>
        <year>2003</year>
        <volume>47</volume>
        <fpage>1241</fpage>
        <lpage>1250</lpage>
        <pub-id pub-id-type="doi">10.1128/AAC.47.4.1241-1250.2003</pub-id>
        <?supplied-pmid 12654653?>
        <pub-id pub-id-type="pmid">12654653</pub-id>
      </element-citation>
    </ref>
    <ref id="R66">
      <label>66</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Heym</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Young</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>The catalase—peroxidase gene and isoniazid resistance of <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>Nature</source>
        <year>1992</year>
        <volume>358</volume>
        <fpage>591</fpage>
        <lpage>593</lpage>
        <pub-id pub-id-type="doi">10.1038/358591a0</pub-id>
        <pub-id pub-id-type="pmid">1501713</pub-id>
      </element-citation>
    </ref>
    <ref id="R67">
      <label>67</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martinez</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Holmes</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Jelfs</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sintchenko</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>Genome sequencing reveals novel deletions associated with secondary resistance to pyrazinamide in MDR <italic toggle="yes">Mycobacterium tuberculosis</italic>
</article-title>
        <source>J Antimicrob Chemother</source>
        <year>2015</year>
        <volume>70</volume>
        <fpage>2511</fpage>
        <lpage>2514</lpage>
        <pub-id pub-id-type="doi">10.1093/jac/dkv128</pub-id>
        <?supplied-pmid 25977398?>
        <pub-id pub-id-type="pmid">25977398</pub-id>
      </element-citation>
    </ref>
    <ref id="R68">
      <label>68</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garrison</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sirén</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Novak</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Hickey</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Eizenga</surname>
            <given-names>JM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Variation graph toolkit improves read mapping by representing genetic variation in the reference</article-title>
        <source>Nat Biotechnol</source>
        <year>2018</year>
        <volume>36</volume>
        <fpage>875</fpage>
        <lpage>879</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.4227</pub-id>
        <?supplied-pmid 30125266?>
        <pub-id pub-id-type="pmid">30125266</pub-id>
      </element-citation>
    </ref>
    <ref id="R69">
      <label>69</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>W-W</given-names>
          </name>
          <name>
            <surname>Asri</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ebler</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Doerr</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Haukness</surname>
            <given-names>M</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>A draft human pangenome reference</article-title>
        <source>Nature</source>
        <year>2023</year>
        <volume>617</volume>
        <fpage>312</fpage>
        <lpage>324</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-023-05896-x</pub-id>
        <?supplied-pmid 37165242?>
        <pub-id pub-id-type="pmid">37165242</pub-id>
      </element-citation>
    </ref>
    <ref id="R70">
      <label>70</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Samarakoon</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Punchihewa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Senanayake</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hammond</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Stevanovski</surname>
            <given-names>I</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Genopo: a nanopore sequencing analysis toolkit for portable Android devices</article-title>
        <source>Commun Biol</source>
        <year>2020</year>
        <volume>3</volume>
        <fpage>538</fpage>
        <pub-id pub-id-type="doi">10.1038/s42003-020-01270-z</pub-id>
        <?supplied-pmid 32994472?>
        <pub-id pub-id-type="pmid">32994472</pub-id>
      </element-citation>
    </ref>
    <ref id="R71">
      <label>71</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gómez-González</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Perdigao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gomes</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Puyen</surname>
            <given-names>ZM</given-names>
          </name>
          <name>
            <surname>Santos-Lazaro</surname>
            <given-names>D</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Genetic diversity of candidate loci linked to <italic toggle="yes">Mycobacterium tuberculosis</italic> resistance to bedaquiline, delamanid and pretomanid</article-title>
        <source>Sci Rep</source>
        <year>2021</year>
        <volume>11</volume>
        <elocation-id>19431</elocation-id>
        <pub-id pub-id-type="doi">10.1038/s41598-021-98862-4</pub-id>
        <?supplied-pmid 34593898?>
        <pub-id pub-id-type="pmid">34593898</pub-id>
      </element-citation>
    </ref>
    <ref id="R72">
      <label>72</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schena</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Nedialkova</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Borroni</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Battaglia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cabibbe</surname>
            <given-names>AM</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Delamanid susceptibility testing of <italic toggle="yes">Mycobacterium tuberculosis</italic> using the resazurin microtitre assay and the BACTEC<sup>TM</sup> MGIT<sup>TM</sup> 960 system</article-title>
        <source>J Antimicrob Chemother</source>
        <year>2016</year>
        <volume>71</volume>
        <fpage>1532</fpage>
        <lpage>1539</lpage>
        <pub-id pub-id-type="doi">10.1093/jac/dkw044</pub-id>
        <?supplied-pmid 27076101?>
        <pub-id pub-id-type="pmid">27076101</pub-id>
      </element-citation>
    </ref>
    <ref id="R73">
      <label>73</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gomes</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Campino</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Marinho</surname>
            <given-names>CRF</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>TG</given-names>
          </name>
          <name>
            <surname>Phelan</surname>
            <given-names>JE</given-names>
          </name>
        </person-group>
        <article-title>Whole genome sequencing reveals large deletions and other loss of function mutations in <italic toggle="yes">Mycobacterium tuberculosis</italic> drug resistance genes</article-title>
        <source>Microb Genom</source>
        <year>2021</year>
        <volume>7</volume>
        <elocation-id>000724</elocation-id>
        <pub-id pub-id-type="doi">10.1099/mgen.0.000724</pub-id>
        <?supplied-pmid 34889724?>
        <pub-id pub-id-type="pmid">34889724</pub-id>
      </element-citation>
    </ref>
    <ref id="R74">
      <label>74</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>De Maio</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Cingolani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bianco</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Salustri</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Palucci</surname>
            <given-names>I</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>First description of the katG gene deletion in a <italic toggle="yes">Mycobacterium tuberculosis</italic> clinical isolate and its impact on the mycobacterial fitness</article-title>
        <source>Int J Med Microbiol</source>
        <year>2021</year>
        <volume>311</volume>
        <fpage>151506</fpage>
        <pub-id pub-id-type="doi">10.1016/j.ijmm.2021.151506</pub-id>
        <?supplied-pmid 33906074?>
        <pub-id pub-id-type="pmid">33906074</pub-id>
      </element-citation>
    </ref>
    <ref id="R75">
      <label>75</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ang</surname>
            <given-names>MLT</given-names>
          </name>
          <name>
            <surname>Zainul Rahim</surname>
            <given-names>SZ</given-names>
          </name>
          <name>
            <surname>de Sessions</surname>
            <given-names>PF</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Koh</surname>
            <given-names>V</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>EthA/R-independent killing of <italic toggle="yes">Mycobacterium tuberculosis</italic> by ethionamide</article-title>
        <source>Front Microbiol</source>
        <year>2017</year>
        <volume>8</volume>
        <elocation-id>710</elocation-id>
        <pub-id pub-id-type="doi">10.3389/fmicb.2017.00710</pub-id>
        <?supplied-pmid 28487681?>
        <pub-id pub-id-type="pmid">28487681</pub-id>
      </element-citation>
    </ref>
    <ref id="R76">
      <label>76</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Allix-Béguec</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Arandjelovic</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Bi</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Beckert</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bonnet</surname>
            <given-names>M</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing</article-title>
        <source>N Engl J Med</source>
        <year>2018</year>
        <volume>379</volume>
        <fpage>1403</fpage>
        <lpage>1415</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa1800474</pub-id>
        <?supplied-pmid 30280646?>
        <pub-id pub-id-type="pmid">30280646</pub-id>
      </element-citation>
    </ref>
    <ref id="R77">
      <label>77</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Köser</surname>
            <given-names>CU</given-names>
          </name>
          <name>
            <surname>Cirillo</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Miotto</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>How to optimally combine genotypic and phenotypic drug susceptibility testing methods for pyrazinamide</article-title>
        <source>Antimicrob Agents Chemother</source>
        <year>2020</year>
        <volume>64</volume>
        <elocation-id>e01003-20</elocation-id>
        <pub-id pub-id-type="doi">10.1128/AAC.01003-20</pub-id>
        <?supplied-pmid 32571824?>
        <pub-id pub-id-type="pmid">32571824</pub-id>
      </element-citation>
    </ref>
    <ref id="R78">
      <label>78</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yadon</surname>
            <given-names>AN</given-names>
          </name>
          <name>
            <surname>Maharaj</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Adamson</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>Y-P</given-names>
          </name>
          <name>
            <surname>Sacchettini</surname>
            <given-names>JC</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide</article-title>
        <source>Nat Commun</source>
        <year>2017</year>
        <volume>8</volume>
        <elocation-id>588</elocation-id>
        <pub-id pub-id-type="doi">10.1038/s41467-017-00721-2</pub-id>
        <?supplied-pmid 28928454?>
        <pub-id pub-id-type="pmid">28928454</pub-id>
      </element-citation>
    </ref>
    <ref id="R79">
      <label>79</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Park</surname>
            <given-names>S-C</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>YO</given-names>
          </name>
          <name>
            <surname>Won</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chun</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Large-scale genomics reveals the genetic characteristics of seven species and importance of phylogenetic distance for estimating pan-genome size</article-title>
        <source>Front Microbiol</source>
        <year>2019</year>
        <volume>10</volume>
        <elocation-id>834</elocation-id>
        <pub-id pub-id-type="doi">10.3389/fmicb.2019.00834</pub-id>
        <?supplied-pmid 31068915?>
        <pub-id pub-id-type="pmid">31068915</pub-id>
      </element-citation>
    </ref>
    <ref id="R80">
      <label>80</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zwyer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Çavusoglu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Ghielmetti</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Pacciarini</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Scaltriti</surname>
            <given-names>E</given-names>
          </name>
          <etal>et al</etal>
        </person-group>
        <article-title>A new nomenclature for the livestock-associated <italic toggle="yes">Mycobacterium tuberculosis</italic> complex based on phylogenomics</article-title>
        <source>Open Res Europe</source>
        <year>2021</year>
        <volume>1</volume>
        <fpage>100</fpage>
        <pub-id pub-id-type="doi">10.12688/openreseurope.14029.2</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
